- Home
- CRVS vs AMBI Comparison
CRVS vs AMBI Comparison
Compare CRVS & AMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- AMBI
- Stock Information
- Founded
- CRVS 2014
- AMBI 1995
- Country
- CRVS United States
- AMBI Brazil
- Employees
- CRVS N/A
- AMBI N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- AMBI Environmental Services
- Sector
- CRVS Health Care
- AMBI Industrials
- Exchange
- CRVS Nasdaq
- AMBI Nasdaq
- Market Cap
- CRVS 257.0M
- AMBI 282.3M
- IPO Year
- CRVS 2016
- AMBI N/A
- Fundamental
- Price
- CRVS $2.99
- AMBI $4.70
- Analyst Decision
- CRVS Strong Buy
- AMBI
- Analyst Count
- CRVS 5
- AMBI 0
- Target Price
- CRVS $12.63
- AMBI N/A
- AVG Volume (30 Days)
- CRVS 715.8K
- AMBI 33.8K
- Earning Date
- CRVS 05-05-2025
- AMBI 01-01-0001
- Dividend Yield
- CRVS N/A
- AMBI N/A
- EPS Growth
- CRVS N/A
- AMBI 250.01
- EPS
- CRVS N/A
- AMBI 0.16
- Revenue
- CRVS N/A
- AMBI $582,477,596.00
- Revenue This Year
- CRVS N/A
- AMBI N/A
- Revenue Next Year
- CRVS N/A
- AMBI N/A
- P/E Ratio
- CRVS N/A
- AMBI $30.45
- Revenue Growth
- CRVS N/A
- AMBI 27.80
- 52 Week Low
- CRVS $1.30
- AMBI $3.07
- 52 Week High
- CRVS $10.00
- AMBI $8.20
- Technical
- Relative Strength Index (RSI)
- CRVS 26.38
- AMBI 46.44
- Support Level
- CRVS $3.06
- AMBI $4.75
- Resistance Level
- CRVS $3.31
- AMBI $6.00
- Average True Range (ATR)
- CRVS 0.36
- AMBI 0.63
- MACD
- CRVS -0.10
- AMBI -0.01
- Stochastic Oscillator
- CRVS 1.11
- AMBI 12.16
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.